Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.48 |
| ▸ | KDM5C | P41229 | 2/20 | 0.47 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.47 |
| ▸ | KDM4B | O94953 | 1/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.44 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | GABRP | O00591 | 1/20 | 0.42 |
| ▸ | GABRD | O14764 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30475719 | 0.81 | PFKFB3 (0.42) | KDM5CKDM5BKDM4BMKNK1MKNK2 | |
| SCHEMBL118817 | 0.81 | KDM4C (0.61) | KDM5CKDM5BKDM4BTAS1R3TAS1R1 | |
| SCHEMBL29957382 | 0.81 | KDM4C (0.61) | KDM5CKDM5BKDM4BTAS1R3TAS1R1 | |
| SCHEMBL27659477 | 0.81 | PARP1 (0.51) | PARP1MKNK1MKNK2ROCK1 | |
| SCHEMBL20011909 | 0.79 | LOXL2 (0.44) | LOXL2F7F3 | |
| Hydrochloric Acid SCHEMBL28045024 | 0.79 | KDM4C (0.59) | KDM5CKDM5BKDM4BTAS1R3TAS1R1 | |
| SCHEMBL1437180 | 0.79 | TAS1R3 (0.48) | KDM5CKDM5BTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL29967026 | 0.79 | TAS1R3 (0.48) | KDM5CKDM5BTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL3569008 | 0.79 | TAS1R3 (0.44) | KDM5CKDM5BTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL2997667 | 0.79 | KDM4E (0.55) | TAS1R3TAS1R1TAS1R2LOXL2PFKFB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12180185-B2 | Compound as protein kinase inhibitor, and pharmaceutical composition comprising thereof | HK INNO.N CORPORATION (KR) | 2024-12-31 | — | — | US | claimed |
| US-11724999-B2 | Inhibitors of RAS-effector protein interactions | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2023-08-15 | — | — | US | claimed |
| US-20220009902-A1 | NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | HK INNO.N CORPORATION (KR) | 2022-01-13 | — | — | US | claimed |
| US-20210047305-A1 | INHIBITORS OF RAS-EFFECTOR PROTEIN INTERACTIONS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-02-18 | — | — | US | claimed |
| EP-3743414-A1 | INHIBITORS OF RAS-EFFECTOR PROTEIN INTERACTIONS | Oxford University Innovation Limited (GB) | 2020-12-02 | — | — | EP | claimed |
| WO-2019145719-A1 | INHIBITORS OF RAS-EFFECTOR PROTEIN INTERACTIONS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2019-08-01 | — | — | WO | claimed |
| CN-103687846-A | Benzylamine derivatives as inhibitors of plasma kallikrein | KALVISTA PHARMACEUTICALS LTD | 2014-03-26 | — | — | CN | claimed |
| CN-101343366-A | Nano-laminal compound with regular array of pyridine and its derivant, and preparation thereof | UNIV SHANGHAI (CN) | 2009-01-14 | — | — | CN | claimed |
| EP-1534687-B1 | 2-PHENYLAMINO-4-TRIFLUOROMETHYL-5-(BENZYL- OR PYRIDIN-4-YLMETHYL)CARBAMOYLPYRIMIDINE DERIVATIVES AS SELECTIVE CB2 CANNABINOID RECEPTOR MODULATORS | GLAXO GROUP LTD (GB) | 2006-09-27 | — | — | EP | claimed |
| EP-1068187-A1 | PYRAZOLE INHIBITORS OF CYTOKINE PRODUCTION | ABBOTT LABORATORIES (US) | 2001-01-17 | — | — | EP | claimed |
| WO-1999051580-A1 | PYRAZOLE INHIBITORS OF CYTOKINE PRODUCTION | ABBOTT LABORATORIES (US) | 1999-10-14 | — | — | WO | claimed |
| US-12534456-B2 | Heterocyclyl pyridines as novel fungicides | BAYER AKTIENGESELLSCHAFT (DE) | 2026-01-27 | — | — | US | disclosed |
| EP-4665733-A1 | AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 | Bristol-Myers Squibb Company (US) | 2025-12-24 | — | — | EP | disclosed |
| CN-113166094-B | Compounds as protein kinase inhibitors and pharmaceutical compositions comprising the same | 怡诺安有限公司 | 2025-05-06 | — | — | CN | disclosed |
| US-20250122174-A1 | Heteroaryl Compounds As HPK1 Inhibitors And Methods Of Using Same | SHENZHEN YUANLI SHENWAN INNOVATIVE MEDICINE CO LTD (CN) | 2025-04-17 | — | — | US | disclosed |
| WO-2005074939-A1 | COMBINATION OF CB2 MODULATORS AND PDE4 INHIBITORS FOR USE IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2005-08-18 | — | — | WO | disclosed |
| EP-1534687-A1 | PYRIMIDINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-06-01 | — | — | EP | disclosed |
| US-6743794-B2 | MULTIDRUG RESISTANCE PROTEIN; CANCER; 3-(9-CHLORO-3-METHYL-4-OXO-5H-ISOXAZOLO(4,3-C)QUINOLIN-5-YL)) CYCLOHEXYL)-2-PIPERIDYLACETAMIDE | ELI LILLY AND COMPANY | 2004-06-01 | — | — | US | disclosed |
| WO-2004018434-A1 | PYRIMIDINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2004-03-04 | — | — | WO | disclosed |
| CN-87104160-A | The N-cyanoalkylisonicotinderivatives derivatives | — | 1988-01-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047305-A1 | INHIBITORS OF RAS-EFFECTOR PROTEIN INTERACTIONS | KRAS, NRAS, HRAS | PARP1 3580/4885KDM5C 4039/4885KDM5B 3882/4885 |
| US-11724999-B2 | Inhibitors of RAS-effector protein interactions | KRAS, NRAS, HRAS | PARP1 3580/4885KDM5C 4039/4885KDM5B 3882/4885 |
| US-20250122174-A1 | Heteroaryl Compounds As HPK1 Inhibitors And Methods Of Using Same | SGK1, HYPK, PCK1 | PARP1 2518/4885KDM5C 3110/4885KDM5B 3221/4885 |
| US-12180185-B2 | Compound as protein kinase inhibitor, and pharmaceutical composition comprising thereof | MAP3K20, MAP3K1, MAP3K15 | PARP1 1984/4885KDM5C 2755/4885KDM5B 2848/4885 |
| US-12534456-B2 | Heterocyclyl pyridines as novel fungicides | CBR1, CBR3, NOX1 | PARP1 3841/4885KDM5C 417/4885KDM5B 1187/4885 |
| US-20220009902-A1 | NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | MAP3K20, MAP3K1, MAP3K15 | PARP1 1998/4885KDM5C 3170/4885KDM5B 3316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.